Source: People's Health Network
When a child runs out of tears, coughs, or has fever, you may think it's just a common cold, it's okay. wrong! This may be because the child is infected with respiratory syncytial virus (RSV), there is currently no vaccine or targeted drugs, and the mortality rate is high.
Director of Beijing Children's Hospital Affiliated to Capital Medical University Ni XinDoes a report
According to the World Health Organization, about 64 million children are infected with RSV every year, and nearly 3.5 million children are admitted to hospital due to severe RSV infection, which is 16 times that of influenza. 200,000 children under 5 years old die from RSV infection every year, which is a major factor in the hospitalization and death of children around the world. There is currently no drug to treat RSV infection.
Recently, the first investigator meeting and project launch meeting of the new anti-respiratory syncytial virus AK0529 China Child Phase III clinical trial, led by the Beijing Children's Hospital affiliated to the Capital Medical University, was held in Beijing. Experts at the meeting said that RSV is unfamiliar to many people, but it is a virus that almost all children under 2 years old will be infected with. The initial stage of RSV infection is runny nose, cough, and fever. Some children will develop bronchitis and or pneumonia. The symptoms generally last for 5-7 days, or even up to 20 days, seriously affecting the life and health of children.
Experts at the meeting said that if a person is infected with RSV in childhood, he may develop childhood asthma or asthma in the future. Since the human body itself cannot produce continuous protective immunity to cope with RSV infection, people can be infected with RSV repeatedly throughout their lives.
Wu Zheng, CEO of Shanghai Aikebai Biopharmaceutical Technology Co., Ltd., gave a report
Wu Zheng, CEO of Shanghai Aikebai Biopharmaceutical Technology Co., Ltd., said in the report that we have established a project to develop new anti-RSV infection drugs and invented a new anti-RSV drug AK0529. The results of the current international Phase II study of AK0529 drug have been completed show that it has excellent antiviral effects. It can inhibit viral infection, reduce viral load, significantly reduce the clinical symptoms of patients, and the drug is highly safe, and no adverse drug-related events have occurred.
Based on the results of a global multi-center Phase II clinical study, Aike Baifa plans to conduct a Phase III clinical trial for drug marketing registration applications in January 2020. The Phase III clinical trial of children will be launched in China first, led by Beijing Children's Hospital affiliated to Capital Medical University, and carried out in 30 centers across the country. It is planned to complete relevant research by mid-2021. This study is the main investigator of Ni Xin, director of the National Children's Medical Center (Beijing) and director of Beijing Children's Hospital Affiliated to Capital Medical University. He pointed out that once AK0529 is completed and successfully launched, the situation where RSV virus infection is generally not targeted drug treatment for decades will be changed, which is of great significance to pediatric clinical practice and is expected to break through the dilemma of no drug available for the disease and fill a big gap in the antiviral field at home and abroad.
"We are confident that we can complete the clinical trial of AK0529 as soon as possible, provide effective treatment plans for RSV infection of major pediatric diseases, meet clinical treatment needs, reduce the incidence of chronic respiratory diseases in patients, and enable children to grow up healthily." Wu Zheng finally said.
